CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance

Tomohiro Koga, Christian M. Hedrich, Masayuki Mizui, Nobuya Yoshida, Kotaro Otomo, Linda A. Lieberman, Thomas Rauen, José C. Crispín, George C. Tsokos

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Tissue inflammation in several autoimmune diseases, including SLE and MS, has been linked to an imbalance of IL-17-producing Th (Th17) cells and Tregs; however, the factors that promote Th17-driven autoimmunity are unclear. Here, we present evidence that the calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased and required during Th17 cell differentiation. Isolation of naive T cells from a murine model of lupus revealed increased levels of CaMK4 following stimulation with Th17-inducing cytokines but not following Treg, Th1, or Th2 induction. Furthermore, naive T cells from mice lacking CaMK4 did not produce IL-17. Genetic or pharmacologic inhibition of CaMK4 decreased the frequency of IL-17-producing T cells and ameliorated EAE and lupus-like disease in murine models. Inhibition of CaMK4 reduced Il17 transcription through decreased activation of the cAMP response element modulator α(CREM- α) and reduced activation of the AKT/mTOR pathway, which is known to enhance Th17 differentiation. Importantly, silencing CaMK4 in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.

Original languageEnglish
Pages (from-to)2234-2245
Number of pages12
JournalJournal of Clinical Investigation
Volume124
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Response Elements
Autoimmunity
Interleukin-17
T-Lymphocytes
Th17 Cells
Autoimmune Diseases
Calcium-Calmodulin-Dependent Protein Kinase Type 4
Cell Differentiation
Cytokines
Inflammation
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Koga, T., Hedrich, C. M., Mizui, M., Yoshida, N., Otomo, K., Lieberman, L. A., ... Tsokos, G. C. (2014). CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 124(5), 2234-2245. https://doi.org/10.1172/JCI73411

CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. / Koga, Tomohiro; Hedrich, Christian M.; Mizui, Masayuki; Yoshida, Nobuya; Otomo, Kotaro; Lieberman, Linda A.; Rauen, Thomas; Crispín, José C.; Tsokos, George C.

In: Journal of Clinical Investigation, Vol. 124, No. 5, 01.01.2014, p. 2234-2245.

Research output: Contribution to journalArticle

Koga, T, Hedrich, CM, Mizui, M, Yoshida, N, Otomo, K, Lieberman, LA, Rauen, T, Crispín, JC & Tsokos, GC 2014, 'CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance', Journal of Clinical Investigation, vol. 124, no. 5, pp. 2234-2245. https://doi.org/10.1172/JCI73411
Koga, Tomohiro ; Hedrich, Christian M. ; Mizui, Masayuki ; Yoshida, Nobuya ; Otomo, Kotaro ; Lieberman, Linda A. ; Rauen, Thomas ; Crispín, José C. ; Tsokos, George C. / CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 5. pp. 2234-2245.
@article{94de501bb55f42eeb10052b93e05dd10,
title = "CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance",
abstract = "Tissue inflammation in several autoimmune diseases, including SLE and MS, has been linked to an imbalance of IL-17-producing Th (Th17) cells and Tregs; however, the factors that promote Th17-driven autoimmunity are unclear. Here, we present evidence that the calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased and required during Th17 cell differentiation. Isolation of naive T cells from a murine model of lupus revealed increased levels of CaMK4 following stimulation with Th17-inducing cytokines but not following Treg, Th1, or Th2 induction. Furthermore, naive T cells from mice lacking CaMK4 did not produce IL-17. Genetic or pharmacologic inhibition of CaMK4 decreased the frequency of IL-17-producing T cells and ameliorated EAE and lupus-like disease in murine models. Inhibition of CaMK4 reduced Il17 transcription through decreased activation of the cAMP response element modulator α(CREM- α) and reduced activation of the AKT/mTOR pathway, which is known to enhance Th17 differentiation. Importantly, silencing CaMK4 in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.",
author = "Tomohiro Koga and Hedrich, {Christian M.} and Masayuki Mizui and Nobuya Yoshida and Kotaro Otomo and Lieberman, {Linda A.} and Thomas Rauen and Crisp{\'i}n, {Jos{\'e} C.} and Tsokos, {George C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1172/JCI73411",
language = "English",
volume = "124",
pages = "2234--2245",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance

AU - Koga, Tomohiro

AU - Hedrich, Christian M.

AU - Mizui, Masayuki

AU - Yoshida, Nobuya

AU - Otomo, Kotaro

AU - Lieberman, Linda A.

AU - Rauen, Thomas

AU - Crispín, José C.

AU - Tsokos, George C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tissue inflammation in several autoimmune diseases, including SLE and MS, has been linked to an imbalance of IL-17-producing Th (Th17) cells and Tregs; however, the factors that promote Th17-driven autoimmunity are unclear. Here, we present evidence that the calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased and required during Th17 cell differentiation. Isolation of naive T cells from a murine model of lupus revealed increased levels of CaMK4 following stimulation with Th17-inducing cytokines but not following Treg, Th1, or Th2 induction. Furthermore, naive T cells from mice lacking CaMK4 did not produce IL-17. Genetic or pharmacologic inhibition of CaMK4 decreased the frequency of IL-17-producing T cells and ameliorated EAE and lupus-like disease in murine models. Inhibition of CaMK4 reduced Il17 transcription through decreased activation of the cAMP response element modulator α(CREM- α) and reduced activation of the AKT/mTOR pathway, which is known to enhance Th17 differentiation. Importantly, silencing CaMK4 in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.

AB - Tissue inflammation in several autoimmune diseases, including SLE and MS, has been linked to an imbalance of IL-17-producing Th (Th17) cells and Tregs; however, the factors that promote Th17-driven autoimmunity are unclear. Here, we present evidence that the calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased and required during Th17 cell differentiation. Isolation of naive T cells from a murine model of lupus revealed increased levels of CaMK4 following stimulation with Th17-inducing cytokines but not following Treg, Th1, or Th2 induction. Furthermore, naive T cells from mice lacking CaMK4 did not produce IL-17. Genetic or pharmacologic inhibition of CaMK4 decreased the frequency of IL-17-producing T cells and ameliorated EAE and lupus-like disease in murine models. Inhibition of CaMK4 reduced Il17 transcription through decreased activation of the cAMP response element modulator α(CREM- α) and reduced activation of the AKT/mTOR pathway, which is known to enhance Th17 differentiation. Importantly, silencing CaMK4 in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=84899760423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899760423&partnerID=8YFLogxK

U2 - 10.1172/JCI73411

DO - 10.1172/JCI73411

M3 - Article

C2 - 24667640

AN - SCOPUS:84899760423

VL - 124

SP - 2234

EP - 2245

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -